Olaparib (Lynparza®) is the first drug based on gene mutations, especially BRCA1 and BRCA2 pathogenic mutations, for the treatment of advanced prostate cancer [4] and was highly expected to mark the dawn of personalized medicine in this field. Here, BRCA1 is linked to prostate carcinoma.